Glucose transporter 1, also known as GLUT-1 antibody or SLC2A1 is a protein in humans encoded by the SLC2A1 gene. GLUT-1 antibody facilitates the transport of glucose across the plasma membranes of mammalian cells. GLUT1 is responsible for the low-level of basal glucose uptake required to sustain respiration in all cells. Several glucose transporter protein isoforms have been identified and shown to function in response to insulin and IGF-1 induced signaling. Immunohistochemical studies have shown GLUT-1 expression in many human tissues including those of the colon, lung, stomach, esophagus and breast. A high expression of GLUT-1 immunoreactivity in cancer has been associated with aggressive behavior and shorter disease-free survival. Hypoxia in cancer has a significant impact on clinical outcome and surrogate markers for tumor hypoxia, such as GLUT-1 and HIF-1 alpha, have shown prognostic significance for patient outcome. Recently, studies have also shown that GLUT-1 was positive in most mesotheliomas, but was negative for reactive mesothelium.
1. Martins FC, et al. Increased transglutaminase 2 and GLUT-1 expression in breast tumors not susceptible to chemoprevention with antioxidants. Tumori. 2009 Mar-Apr; 95(2):227-32.
2. Robey IF, et al. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia. 2008 Aug; 10(8):745-56.
3. Li J, et al. Significant increase of glucose transport activity in breast cancer. Zhonghua Bing Li Xue Za Zhi. 2008 Feb; 37(2):103-8.
4. Afify A, et al. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Acta Cytol. 2005 Nov-Dec; 49(6):621-6.
5. Stackhouse BL, et al. Measurement of glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res Treat. 2005 Oct; 93(3):247-53.
6. De Schutter H, et al. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer. 2005 Apr 25; 5:42.
7. Kato Y, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007 Feb;20(2):215-20.
8. Mendez LE, et al. Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol Oncol. 2002 Aug; 86(2):138-43.
9. Sakashita M, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001 Jan; 37(2):204-9.
10. Haber RS, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998 Jul 1; 83(1):34-40.
11. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
12. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.